## Michelle Monje

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4094025/publications.pdf Version: 2024-02-01

		31976	30087
117	17,034	53	103
papers	citations	h-index	g-index
135	135	135	19403
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro-Oncology, 2022, 24, 141-152.	1.2	9
2	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nature Medicine, 2022, 28, 333-344.	30.7	105
3	GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 2022, 603, 934-941.	27.8	339
4	Neural Signaling in Cancer. Annual Review of Neuroscience, 2022, 45, 199-221.	10.7	10
5	Inhibiting USP16 rescues stem cell aging and memory in an Alzheimerâ $\in$ $^{ m Ms}$ model. ELife, 2022, 11, .	6.0	6
6	Maladaptive myelination promotes generalized epilepsy progression. Nature Neuroscience, 2022, 25, 596-606.	14.8	33
7	H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape. Cell Reports, 2022, 39, 110836.	6.4	16
8	Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. Nature Communications, 2022, 13, 2785.	12.8	29
9	MODL-17. The Childhood Brain Cancer Cell Line Atlas: A Resource for Biomarker Identification and Therapeutic Development. Neuro-Oncology, 2022, 24, i172-i172.	1.2	0
10	Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell, 2022, 185, 2452-2468.e16.	28.9	237
11	Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. Nature Cancer, 2022, 3, 976-993.	13.2	23
12	The bright and the dark side of myelin plasticity: Neuron-glial interactions in health and disease. Seminars in Cell and Developmental Biology, 2021, 116, 10-15.	5.0	10
13	TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro-Oncology, 2021, 23, 76-87.	1.2	24
14	MRI-based radiomics for prognosis of pediatric diffuse intrinsic pontine glioma: an international study. Neuro-Oncology Advances, 2021, 3, vdab042.	0.7	14
15	Partitioned glioma heritability shows subtype-specific enrichment in immune cells. Neuro-Oncology, 2021, 23, 1304-1314.	1.2	12
16	NF1 mutation drives neuronalÂactivity-dependent initiation of optic glioma. Nature, 2021, 594, 277-282.	27.8	91
17	EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG. Neuro-Oncology, 2021, 23, i49-i50.	1.2	6
18	Microglia in Cancer Therapy-Related Cognitive Impairment. Trends in Neurosciences, 2021, 44, 441-451.	8.6	56

#	Article	IF	CITATIONS
19	HGG-06. EARLY GABAERGIC NEURONAL LINEAGE DEFINES DEPENDENCIES IN HISTONE H3 G34R/V GLIOMA. Neuro-Oncology, 2021, 23, i18-i18.	1.2	Ο
20	Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. Nature Communications, 2021, 12, 4089.	12.8	27
21	Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas. , 2021, , .		7
22	Microenvironmental interactions of oligodendroglial cells. Developmental Cell, 2021, 56, 1821-1832.	7.0	15
23	Unravelling the Mechanisms of Cancer-Related Cognitive Dysfunction in Non–Central Nervous System Cancer. JAMA Oncology, 2021, 7, 1311.	7.1	6
24	Disruption of Oligodendrogenesis Impairs Memory Consolidation in Adult Mice. Neuron, 2020, 105, 150-164.e6.	8.1	263
25	The Neural Regulation of Cancer. Annual Review of Cancer Biology, 2020, 4, 371-390.	4.5	12
26	A comparative study of brain tumor cells from different age and anatomical locations using 3D biomimetic hydrogels. Acta Biomaterialia, 2020, 116, 201-208.	8.3	10
27	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. Cell Reports, 2020, 33, 108286.	6.4	39
28	Treating cancer therapy–related cognitive impairment. Nature Medicine, 2020, 26, 1174-1175.	30.7	2
29	NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors—Histone Mutated Midline Glioma Workshop Proceedings*. Neuro-Oncology Advances, 2020, 2, vdaa007.	0.7	4
30	Synaptic Communication in Brain Cancer. Cancer Research, 2020, 80, 2979-2982.	0.9	22
31	Understanding the Deadly Silence of Posterior Fossa A Ependymoma. Molecular Cell, 2020, 78, 999-1001.	9.7	5
32	Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. Neuro-Oncology, 2020, 22, 1302-1314.	1.2	42
33	Activity Shapes Neural Circuit Form and Function: A Historical Perspective. Journal of Neuroscience, 2020, 40, 944-954.	3.6	62
34	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nature Medicine, 2020, 26, 712-719.	30.7	172
35	Roadmap for the Emerging Field of Cancer Neuroscience. Cell, 2020, 181, 219-222.	28.9	182
36	CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. Genome Biology, 2020, 21, 83.	8.8	76

#	Article	IF	CITATIONS
37	CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering. Blood, 2020, 136, 53-54.	1.4	28
38	DIPG-32. AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2020, 22, iii293-iii293.	1.2	0
39	Pediatric Brain Tumors. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 1553-1583.	0.8	6
40	Bespoke myelin tailored to neuron type. Science, 2020, 370, 1414-1415.	12.6	2
41	DIPG-29. PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE (PI3K) INHIBITION DRIVES PROTEIN KINASE C ACTIVATION (PKC) IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2020, 22, iii292-iii293.	1.2	1
42	EXTH-67. PHARMACOLOGIC INHIBITION OF LYSINE SPECIFIC DEMETHYLASE-1 (LSD1) AS AN ADJUVANT IMMUNE-SENSITIZATION STRATEGY IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2020, 22, ii102-ii102.	1.2	0
43	EXTH-37. TARGETING EPIGENETIC VULNERABILITIES IDENTIFIED FROM A CRISPR SCREEN IN H3.3K27M DIPG. Neuro-Oncology, 2020, 22, ii95-ii95.	1.2	0
44	NIMG-31. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. Neuro-Oncology, 2020, 22, ii154-ii154.	1.2	0
45	IMMU-55. GD2 IS A MACROPHAGE CHECKPOINT MOLECULE AND COMBINED GD2/CD47 BLOCKADE RESULTS IN SYNERGISTIC EFFECTS AGAINST GD2 POSITIVE MALIGNANCIES. Neuro-Oncology, 2020, 22, ii116-ii116.	1.2	0
46	TMOD-13. RESEARCH RESOURCES FOR OLIGODENDROGLIOMA NOW AVAILABLE TO RESEARCH COMMUNITY. Neuro-Oncology, 2020, 22, ii230-ii230.	1.2	0
47	EPCO-26. PROJECT HOPE: "PEDIATRIC AND AYA HIGH-GRADE GLIOMA OMICS PROJECT― A LONGITUDINAL MOLECULAR LANDSCAPE OF HIGH-GRADE GLIOMAS RESOLVED AT SINGLE-CELL LEVEL. Neuro-Oncology, 2020, 22, ii74-ii75.	1.2	0
48	TAMI-21. MALIGNANT GLIOMAS REMODEL FUNCTIONAL NEURAL CIRCUITS THROUGH PARACRINE SIGNALING WHICH CONFERS A NEGATIVE PROGNOSIS. Neuro-Oncology, 2020, 22, ii217-ii218.	1.2	0
49	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell, 2019, 178, 835-849.e21.	28.9	1,408
50	Inflaming glioma growth. Neuro-Oncology, 2019, 21, 1213-1214.	1.2	0
51	Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials. Current Treatment Options in Neurology, 2019, 21, 37.	1.8	73
52	Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State. Molecular Cell, 2019, 76, 965-980.e12.	9.7	110
53	The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nature Communications, 2019, 10, 2235.	12.8	96
54	DIPG-03. TARGETING PI3K USING THE BLOOD BRAIN BARRIER PENETRABLE INHIBITOR, GDC-0084, FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2019, 21, ii68-ii68.	1.2	5

#	Article	IF	CITATIONS
55	ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Communications Biology, 2019, 2, 156.	4.4	73
56	Loss of Adaptive Myelination Contributes to Methotrexate Chemotherapy-Related Cognitive Impairment. Neuron, 2019, 103, 250-265.e8.	8.1	177
57	Developmental origins and emerging therapeutic opportunities for childhood cancer. Nature Medicine, 2019, 25, 367-376.	30.7	112
58	Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Science Translational Medicine, 2019, 11, .	12.4	129
59	TMIC-46. GLIOMA-INDUCED SYNAPTOGENESIS IS ENRICHED WITHIN FUNCTIONAL CONNECTIVITY NETWORK HUBS AND INFLUENCES LANGUAGE PROCESSING IN ADULT IDH WT GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi257-vi258.	1.2	0
60	c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature, 2019, 576, 293-300.	27.8	480
61	Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets. Current Opinion in Oncology, 2019, 31, 522-530.	2.4	45
62	Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment. Current Opinion in Oncology, 2019, 31, 531-539.	2.4	26
63	Electrical and synaptic integration of glioma into neural circuits. Nature, 2019, 573, 539-545.	27.8	706
64	International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2019, 141, 253-263.	2.9	30
65	CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clinical Cancer Research, 2019, 25, 2560-2574.	7.0	369
66	Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment. Cell, 2019, 176, 43-55.e13.	28.9	222
67	Monosynaptic tracing maps brain-wide afferent oligodendrocyte precursor cell connectivity. ELife, 2019, 8, .	6.0	49
68	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 2018, 360, 331-335.	12.6	461
69	Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nature Medicine, 2018, 24, 572-579.	30.7	321
70	Bad wrap: Myelin and myelin plasticity in health and disease. Developmental Neurobiology, 2018, 78, 123-135.	3.0	70
71	DIPG-41. IDENTIFICATION OF BIRC5 AS A NOVEL THERAPEUTIC TARGET FOR DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, i57-i57.	1.2	1
72	IMMU-19. LSD1 MODULATES NK CELL IMMUNOTHERAPY THROUGH AN ONCO-IMMUNOGENIC GENE SIGNATURE IN DIPG. Neuro-Oncology, 2018, 20, i102-i102.	1.2	2

#	Article	IF	CITATIONS
73	Open questions: why are babies rarely born with cancer?. BMC Biology, 2018, 16, 129.	3.8	6
74	DIPG-69. CHARACTERISTICS OF PATIENTS a‰¥ 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2018, 20, i63-i63.	1.2	1
75	An active role for neurons in glioma progression: making sense of Scherer's structures. Neuro-Oncology, 2018, 20, 1292-1299.	1.2	50
76	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nature Medicine, 2018, 24, 1204-1215.	30.7	133
77	Myelin Plasticity and Nervous System Function. Annual Review of Neuroscience, 2018, 41, 61-76.	10.7	153
78	Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathologica Communications, 2018, 6, 51.	5.2	115
79	DIPG-22. A PHASE 1 TRIAL OF THE HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY DIFFUSE INTRINSIC PONTINE GLIOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY. Neuro-Oncology, 2018, 20, i53-i53.	1.2	10
80	Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-Oncology, 2017, 19, now101.	1.2	217
81	Settling a Nervous Stomach: The Neural Regulation of Enteric Cancer. Cancer Cell, 2017, 31, 1-2.	16.8	34
82	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. Journal of Neuro-Oncology, 2017, 132, 323-331.	2.9	27
83	Brain Perfusion and Diffusion Abnormalities in Children Treated for Posterior Fossa Brain Tumors. Journal of Pediatrics, 2017, 185, 173-180.e3.	1.8	21
84	Neuronal Activity in Ontogeny and Oncology. Trends in Cancer, 2017, 3, 89-112.	7.4	80
85	Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 31, 635-652.e6.	16.8	290
86	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science, 2017, 355, .	12.6	743
87	Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Science Translational Medicine, 2017, 9, .	12.4	306
88	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 32, 520-537.e5.	16.8	716
89	Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature, 2017, 549, 533-537.	27.8	350
90	Wrapped to Adapt: Experience-Dependent Myelination. Neuron, 2017, 95, 743-756.	8.1	175

#	Article	IF	CITATIONS
91	Neural Precursor-Derived Pleiotrophin Mediates Subventricular Zone Invasion by Glioma. Cell, 2017, 170, 845-859.e19.	28.9	159
92	Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro-Oncology, 2017, 19, 1279-1280.	1.2	93
93	A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG). Journal of Visualized Experiments, 2017, , .	0.3	33
94	Neuronal activity in the glioma microenvironment. Current Opinion in Neurobiology, 2017, 47, 156-161.	4.2	41
95	HGG-22. TARGETING NEURONAL ACTIVITY-REGULATED NEUROLIGIN-3 DEPENDENCY FOR HIGH-GRADE GLIOMA THERAPY. Neuro-Oncology, 2017, 19, iv27-iv27.	1.2	1
96	Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets. Current Neuropharmacology, 2017, 15, 88-97.	2.9	88
97	Neurologic Complications of Oncologic Therapy. , 2016, , 125-142.		1
98	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature, 2016, 539, 309-313.	27.8	875
99	Myelin plasticity in the central nervous system. Neuropharmacology, 2016, 110, 563-573.	4.1	84
100	PTPS-24MECHANISMS OF DIFFUSE INTRINSIC PONTINE GLIOMA METASTASIS TO THE SUBVENTRICULAR ZONE. Neuro-Oncology, 2015, 17, v184.3-v184.	1.2	0
101	BT-02 * FUNCTIONALLY-DEFINED THERAPEUTIC TARGETS IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2015, 17, iii3-iii3.	1.2	2
102	Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion. Cell, 2015, 161, 803-816.	28.9	550
103	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559.	30.7	473
104	Neuronal Activity Promotes Oligodendrogenesis and Adaptive Myelination in the Mammalian Brain. Science, 2014, 344, 1252304.	12.6	1,057
105	Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature Genetics, 2014, 46, 457-461.	21.4	423
106	Human pontine glioma cells can induce murine tumors. Acta Neuropathologica, 2014, 127, 897-909.	7.7	63
107	Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathologica, 2014, 128, 605-607.	7.7	74
108	Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature Medicine, 2014, 20, 732-740.	30.7	255

#	Article	IF	CITATIONS
109	ME-04 * SUBVENTRICULAR SPREAD OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2014, 16, v120-v120.	1.2	0
110	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	16.8	633
111	Functional and structural differences in the hippocampus associated with memory deficits in adult survivors of acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2013, 60, 293-300.	1.5	49
112	Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behavioural Brain Research, 2012, 227, 376-379.	2.2	172
113	Neurological complications following treatment of children with brain tumors. Journal of Pediatric Rehabilitation Medicine, 2011, 4, 31-36.	0.5	16
114	Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4453-4458.	7.1	262
115	Cranial radiation therapy and damage to hippocampal neurogenesis. Developmental Disabilities Research Reviews, 2008, 14, 238-242.	2.9	89
116	Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy. Oncologist, 2008, 13, 1285-1295.	3.7	297
117	Excitation-Neurogenesis Coupling in Adult Neural Stem/Progenitor Cells. Neuron, 2004, 42, 535-552.	8.1	606